Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH

 Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH

Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH

Shots:

  • The P-III (1002-047) study involve assessing of Bempedoic Acid (180 mg qd) vs PBO in 779 patients in ratio 2:1 with ASCVD OR HeFH for 52 wks.
  • P-III Study 2 or 1002-047 results: LDL-C lowering 18%; reduction in High-Sensitivity C-reactive protein (hsCRP) 19%; Reduction in Hemoglobin A1c (HbA1c) 0.21%; MACE events 3/4/5 component (2.7%, 5.7%, 6.1% vs 4.7%, 7.8%, 8.2%); safe and well tolerated
  • Bempedoic Acid PO is a novel qd ACLi helps in lowering LDL-C. In 2016, Esperion initiated onset of global P-III trial with five studies in 4000 patients evaluating bempedoic acid and bempedoic acid + ezetimibe

Click here to read full press release/ article | Ref: Esperion Therapeutics| Image: Cardio Brief

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post